Boeing Expert Says 737 MAX Freeze & Certification Challenges May Lead To Customer Loss: BofA Analyst
BofA Analyst discusses with Chris Brady about FAA's production freeze of Boeing's 737 MAX and potential implications for certification.
Pfizer’s COVID-19 Treatment Paxlovid Will No Longer Be Available For Emergency Use After This Date, FDA Revises Label
FDA revises emergency use authorization for Pfizer's Paxlovid, impacting distribution and treatment of mild-to-moderate COVID-19. Transitions from March 8.
Battleground For Oil Majors: BP Activist Investor Calls For Cut In Green Energy Pledges
Hedge fund says BP's energy transition policies are hurting the share price.
Sarepta Therapeutics’ Next-Gen Duchenne Muscular Therapy Shows Efficacy At Less Frequent Dosing
Sarepta Therapeutics unveils results from MOMENTUM study's Phase 2 trial for SRP-5051, a next-gen PPMO treatment targeting Duchenne muscular dystrophy.
Microsoft Analysts To Focus On Tech Giant’s Expansive AI Ambitions Following Q2 Earnings
As a key distributor of transformative AI technology, Microsoft positions itself for substantial financial gains.
Google To Focus On AI Positioning, Impact Of Layoffs And Shareholder Returns After Q4 Earnings
Google will be reporting its fourth-quarter earnings on Jan. 30. Wall Street expects $1.59 in EPS and $85.22 billion in revenues.
AI, Biotech, Energy Sectors Expect M&A Revival For 2024
The AI market, along with energy and biotech, are ripe for M&A following the worst performance in almost a decade for deal-making in 2023.
Hope for Kidney Cancer Patients, Merck’s Keytruda Cuts Risk Of Death By 38% Following Surgery
Results from Merck's Phase 3 KEYNOTE-564 trial. Keytruda, an adjuvant treatment for renal cell carcinoma, shows a 38% improvement in overall survival at 57.2 months.
Dutch Health Tech Firm Philips Stops US Sales Of Respiratory Devices Under Finalized Consent Decree Over Device Recall
Philips' Q4 earnings and FDA settlement insights. Learn about the consent decree, actions, future plans for Philips Respironics in the U.S. International services remain unaffected. Philips' 2024 forecasts and financial outlook.
Bristol Myers’ Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients
Results from Bristol Myers Squibb's Phase 3 CheckMate -67T trial on subcutaneous Opdivo (nivolumab) for advanced clear cell renal cell carcinoma. Noninferiority compared to IV Opdivo.